EIC Accelerator

Blykalla is a Swedish company focused on the development and production of advanced small modular reactors (SMRs). Drawing on more than 25 years of research, its reactor concepts aim to provide reliable baseload energy to support a fossil-free energy transition. The company develops lead-cooled reactor designs, featuring cores configured to achieve criticality with enriched uranium oxide fuels, enabling clients to develop, license, and operate small lead-cooled reactors in Sweden. Blykalla emphasizes safety and modularity, offering scalable power solutions for diverse sites while reducing carbon emissions.

Blykalla is a Swedish company focused on the development and production of advanced small modular reactors (SMRs). Drawing on more than 25 years of research, its reactor concepts aim to provide reliable baseload energy to support a fossil-free energy transition. The company develops lead-cooled reactor designs, featuring cores configured to achieve criticality with enriched uranium oxide fuels, enabling clients to develop, license, and operate small lead-cooled reactors in Sweden. Blykalla emphasizes safety and modularity, offering scalable power solutions for diverse sites while reducing carbon emissions.

PharmNovo AB, established in 2008 and headquartered in Lund, Sweden, specializes in developing novel therapeutic drugs for neuro diseases, with a focus on reducing chronic pain through neuroscience and translational medicine. The company's primary product, PN6047, is designed to alleviate chronic pain and combat hypersensitivity disorders by targeting Delta Opioid Receptors (DORAs), distinct from traditional opioids that often lead to addiction and toxicity. PharmNovo aims to address the significant unmet medical need for safe and effective chronic pain treatments, affecting approximately 30% of adults in the United States and Europe.

Gedea Biotech develops an antibiotic-free treatment for vaginal fungal infections using its substance GA101. This natural substance lowers pH, provides physical barrier protection, and inhibits biofilm formation. The company's first product is a topical treatment for vaginal fungal infections.

Qlucore is a prominent provider of advanced bioinformatics software designed for research and precision diagnostics in the life sciences. Founded in 2007 by researchers from Lund University in Sweden, the company aims to simplify the analysis of complex data generated in the fields of genetics and proteomics. Its flagship product, Qlucore Omics Explorer, is a user-friendly bioinformatics tool that enables researchers, technicians, and physicians to easily interpret and visualize large datasets. Additionally, Qlucore offers Qlucore Diagnostics, an AI-powered platform for multi-omics companion and precision diagnostics that integrates with various data-generating instruments. With a global presence, Qlucore serves customers in approximately 35 countries, including leading pharmaceutical companies, hospitals, and academic institutions.